PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26199949-12 2015 gag-specific T-cell responses were detected in 63% of participants by interferon-gamma enzyme-linked immunospot at the highest dose post boost. Glycosaminoglycans 0-3 interferon gamma Homo sapiens 70-86 24114722-2 2014 Gag-specific responses were measured by IFN-gamma ELISpot. Glycosaminoglycans 0-3 interferon gamma Homo sapiens 40-49 25454870-9 2014 This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-gamma and IL-2 production in response to Gag (p=0.0122) and elevated IFN-gamma production in response to Tat (p=0.041) at week 48 compared to baseline. Glycosaminoglycans 166-169 interferon gamma Homo sapiens 121-130 23616666-9 2013 The advantage of Gag-specific cells may result from their enhanced ability to mediate lysis of infected cells (evidenced by a higher capacity to degranulate and to mediate VIA) and to simultaneously produce IFN-gamma. Glycosaminoglycans 17-20 interferon gamma Homo sapiens 207-216 23172685-5 2013 Interestingly, Gag-specific DN T-cell responses were found in 3/13 (23%) HIV-exposed seronegative individuals (Group A), involving both DN/alphabeta(+) and DN/gammadelta(+) T-cells through MIP1beta and IFNgamma production. Glycosaminoglycans 15-18 interferon gamma Homo sapiens 202-210 21533229-5 2011 The overall profiles of cytokine responses to Gag and Ad5 had similar combinations of induced Th1- and Th2-type cytokines, including IFN-gamma, IL-2, TNF-alpha, IP-10, IL-13, and IL-10, although the Ad5-specific responses were uniformly higher than the Gag-specific responses (p<0.0001 for 9 out of 11 significantly expressed analytes). Glycosaminoglycans 46-49 interferon gamma Homo sapiens 133-142 19352428-4 2009 Gag-specific IFN-gamma-producing CD4+ T cell responses were detected in 261/373 (70%) subjects, with the Gag responders having a significantly lower viral load and higher CD4 count than those with no detectable Gag response (p<0.0001 for both parameters). Glycosaminoglycans 0-3 interferon gamma Homo sapiens 13-22 21857901-8 2011 T-cell responses, detected by interferon-gamma (IFN-gamma) ELISpot to global potential T-cell epitopes (PTEs) were observed in 70.8% (136/192) of vaccine recipients overall, most frequently to Gag (54.7%) and to Env (54.2%). Glycosaminoglycans 193-196 interferon gamma Homo sapiens 48-57 20179574-9 2010 CONCLUSION: In all the aforementioned phases of HIV infection, the large majority of gag-specific CD4 T lymphocytes cannot be identified by the sole expression of interleukin-2 and interferon-gamma, which is early impaired. Glycosaminoglycans 85-88 interferon gamma Homo sapiens 181-197 19352428-4 2009 Gag-specific IFN-gamma-producing CD4+ T cell responses were detected in 261/373 (70%) subjects, with the Gag responders having a significantly lower viral load and higher CD4 count than those with no detectable Gag response (p<0.0001 for both parameters). Glycosaminoglycans 105-108 interferon gamma Homo sapiens 13-22 19352428-4 2009 Gag-specific IFN-gamma-producing CD4+ T cell responses were detected in 261/373 (70%) subjects, with the Gag responders having a significantly lower viral load and higher CD4 count than those with no detectable Gag response (p<0.0001 for both parameters). Glycosaminoglycans 105-108 interferon gamma Homo sapiens 13-22 19352428-8 2009 CONCLUSIONS/SIGNIFICANCE: These data indicate that in chronic untreated clade C HIV-1 infection, IFN-gamma-secreting Gag-specific CD4+ T cell responses are immunodominant, directed at multiple distinct epitopes, and associated with viral control. Glycosaminoglycans 117-120 interferon gamma Homo sapiens 97-106 18849196-6 2008 To learn this, we examined Gag-specific IgG production in sera and Gag-specific IFN gamma mRNA expression in peripheral blood mononuclear cells (PBMC) in guinea pigs vaccinated with rBCG-SIVgag i.d. Glycosaminoglycans 67-70 interferon gamma Homo sapiens 80-89 18849196-2 2008 In a previous report, we demonstrated that recombinant BCG (rBCG) expressing the full-length gag gene of simian immunodeficiency virus (SIV) (rBCG-SIVgag) induced Gag-specific delayed-type hypersensitivity, T cell proliferation, gamma interferon (IFN gamma), and serum IgG responses in guinea pigs immunized intradermally (i.d.) Glycosaminoglycans 93-96 interferon gamma Homo sapiens 247-256 18849196-2 2008 In a previous report, we demonstrated that recombinant BCG (rBCG) expressing the full-length gag gene of simian immunodeficiency virus (SIV) (rBCG-SIVgag) induced Gag-specific delayed-type hypersensitivity, T cell proliferation, gamma interferon (IFN gamma), and serum IgG responses in guinea pigs immunized intradermally (i.d.) Glycosaminoglycans 163-166 interferon gamma Homo sapiens 247-256 18849196-10 2008 The enhancement of IFN gamma mRNA expression by in vitro restimulation with Gag antigen was also detected in PBMC from the two immunization groups throughout the 3-year observation period. Glycosaminoglycans 76-79 interferon gamma Homo sapiens 19-28 18849196-14 2008 and oral inoculations of rBCG-SIVgag elicit stable, strong, Gag-specific serum IgG production while exhibiting the different kinetics of Gag-specific IFN gamma responses between i.d. Glycosaminoglycans 137-140 interferon gamma Homo sapiens 150-159 15580653-4 2005 The circulating gag-specific CD8(+) T cells in fresh blood reliably produced IFN-gamma but lacked IL-2 and high perforin levels and failed to expand significantly during culture with mature DC presenting HIV-1 gag peptides. Glycosaminoglycans 16-19 interferon gamma Homo sapiens 77-86 16971807-4 2006 These cells not only express and secrete the HIV p24 antigen after electroporation with codon-optimized HIV-1 gag mRNA, but can also be used to in vitro reactivate Gag antigen-specific interferon-gamma-producing CD4 and CD8 autologous T-cells. Glycosaminoglycans 164-167 interferon gamma Homo sapiens 185-201 16730772-5 2006 Analysis of cellular immune responses revealed slower response rates in virus-specific IFN-gamma production to SIV Gag in the Depo-treated macaques. Glycosaminoglycans 115-118 interferon gamma Homo sapiens 87-96 17143825-9 2007 CD8+ T cell levels specific for each pool of peptides were similar in both groups, but cells mainly contributing to HIV Gag-specific responses in coinfected patients were CCL4 positive and interferon-gamma negative, whereas for HIV-monoinfected subjects, the response was dominated by CCL4-positive and interferon-gamma-positive cells. Glycosaminoglycans 120-123 interferon gamma Homo sapiens 189-205 17143825-9 2007 CD8+ T cell levels specific for each pool of peptides were similar in both groups, but cells mainly contributing to HIV Gag-specific responses in coinfected patients were CCL4 positive and interferon-gamma negative, whereas for HIV-monoinfected subjects, the response was dominated by CCL4-positive and interferon-gamma-positive cells. Glycosaminoglycans 120-123 interferon gamma Homo sapiens 303-319 15990567-6 2005 RESULTS: Absolute numbers, but not percentages, of Gag-specific IFN-gamma-, IL-2- or IFN-gamma/IL-2-producing CD4 T cells were increased in treated compared with untreated individuals up to 2 years after seroconversion. Glycosaminoglycans 51-54 interferon gamma Homo sapiens 64-73 15919923-5 2005 SIV Gag-specific T-cell responses were detected in peripheral blood by MHC class I tetramer staining (peak, 0.07 to 0.2% CD8(+) T cells at week 2) and gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assays (peak, 50 to 250 spot forming cells/10(6) peripheral blood mononuclear cell at week 3). Glycosaminoglycans 4-7 interferon gamma Homo sapiens 151-178 15821391-5 2005 Gag-specific T cells mainly secrete interleukin-2 in ESN and interferon-gamma in HIV patients. Glycosaminoglycans 0-3 interferon gamma Homo sapiens 61-77 14980480-7 2004 These Gag-specific IELs expressed the activation marker CD69 and produced IFN-gamma, suggesting an active immune response in this locale. Glycosaminoglycans 6-9 interferon gamma Homo sapiens 74-83 15345313-3 2004 Continuous expression of Gag and Env proteins was detected in stably transduced BLCL, which induced Gag- or Env-specific T cell responses, as measured by both IFNgamma-ELISPOT and chromium release assays, upon in vitro stimulation of PBMC from the SHIV89.6P-infected monkeys. Glycosaminoglycans 25-28 interferon gamma Homo sapiens 159-167 10328871-0 1999 Binding of interferon gamma by glycosaminoglycans: a strategy for localization and/or inhibition of its activity. Glycosaminoglycans 31-49 interferon gamma Homo sapiens 11-27 12444145-10 2002 The Gag-specific IFN-gamma(+)IL-2(+) CD4 response also correlated positively with the percentage of Gag-specific IFN-gamma(+) CD8 T cells in these subjects. Glycosaminoglycans 4-7 interferon gamma Homo sapiens 113-122 14571181-4 2003 Gag p24-specific and total Vbeta+ CD4 cells that expressed MIP-1beta, IFN-gamma and IL-2 were enumerated by intracytoplasmic cytokine staining. Glycosaminoglycans 0-3 interferon gamma Homo sapiens 70-79 12444145-9 2002 The percentage and absolute number of Gag-specific IFN-gamma(+)IL-2(+) but not of IFN-gamma(+)IL-2(-) CD4s correlated inversely with virus load. Glycosaminoglycans 38-41 interferon gamma Homo sapiens 51-60 12444145-10 2002 The Gag-specific IFN-gamma(+)IL-2(+) CD4 response also correlated positively with the percentage of Gag-specific IFN-gamma(+) CD8 T cells in these subjects. Glycosaminoglycans 4-7 interferon gamma Homo sapiens 17-26 10961890-1 2000 Glycosaminoglycans (GAG) are a group of negatively charged molecules that have been shown to bind and directly regulate the bioactivity of growth factors and cytokines such as basic fibroblast growth factor, transforming growth factor-beta, IL-7, and interferon-gamma. Glycosaminoglycans 0-18 interferon gamma Homo sapiens 251-267 10961890-1 2000 Glycosaminoglycans (GAG) are a group of negatively charged molecules that have been shown to bind and directly regulate the bioactivity of growth factors and cytokines such as basic fibroblast growth factor, transforming growth factor-beta, IL-7, and interferon-gamma. Glycosaminoglycans 20-23 interferon gamma Homo sapiens 251-267 10857760-0 2000 Glycosaminoglycans alter the conformation of interferon-gamma. Glycosaminoglycans 0-18 interferon gamma Homo sapiens 45-61 10717345-3 2000 FPV gag/pol-IFNgamma vaccinations were safe and enhanced T cell proliferative responses to Gag antigens (but not control tetanus antigens). Glycosaminoglycans 91-94 interferon gamma Homo sapiens 12-20 10383394-4 1999 We found that treatment of HASMC with chondroitinase ABC, an enzyme that degrades chondroitin sulfate GAG, reduced IFN-gamma binding by more than 50%. Glycosaminoglycans 102-105 interferon gamma Homo sapiens 115-124 10383394-9 1999 The interaction of IFN-gamma with chondroitin sulfate GAG was confirmed by affinity chromatography of isolated cell-associated 35S-, 3H-labeled PG on a column with immobilized IFN-gamma. Glycosaminoglycans 54-57 interferon gamma Homo sapiens 19-28 10383394-9 1999 The interaction of IFN-gamma with chondroitin sulfate GAG was confirmed by affinity chromatography of isolated cell-associated 35S-, 3H-labeled PG on a column with immobilized IFN-gamma. Glycosaminoglycans 54-57 interferon gamma Homo sapiens 176-185 9330666-0 1997 Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis of retrobulbar fibroblasts induced by interferon gamma. Glycosaminoglycans 61-78 interferon gamma Homo sapiens 127-143 9825824-0 1998 Sulfation-dependent down-regulation of interferon-gamma-induced major histocompatibility complex class I and II and intercellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans. Glycosaminoglycans 197-215 interferon gamma Homo sapiens 39-55 9825824-8 1998 Heparin and supersulfated glycosaminoglycans (GAGs) were able to bind to IFN-gamma, whereas N-desulfated N-acetylated GAGs with a low amount of sulfate were not. Glycosaminoglycans 26-44 interferon gamma Homo sapiens 73-82 9825824-8 1998 Heparin and supersulfated glycosaminoglycans (GAGs) were able to bind to IFN-gamma, whereas N-desulfated N-acetylated GAGs with a low amount of sulfate were not. Glycosaminoglycans 46-50 interferon gamma Homo sapiens 73-82 9067536-2 1997 In this study the mechanism by which the glycosaminoglycan (GAG) heparin antagonizes the activation of a model endothelium by IFN-gamma was investigated. Glycosaminoglycans 41-58 interferon gamma Homo sapiens 126-135 9067536-4 1997 Treatment of the cells with chlorate, a metabolic inhibitor of GAG sulphation, was found to reduce both the subsequent binding of IFN-gamma and its ability to induce expression of class II MHC antigens. Glycosaminoglycans 63-66 interferon gamma Homo sapiens 130-139 9067536-7 1997 These results appear to demonstrate that IFN-gamma is sequestered at the surface of endothelial cells by electrostatic interaction between specific basic amino acid residues and sulphated domains on HS, the most abundant endothelial GAG. Glycosaminoglycans 233-236 interferon gamma Homo sapiens 41-50 9330666-13 1997 Both spontaneous and IFN-gamma-induced GAG synthesis of REF was inhibited by Ptx (100, 500 and 1000 mg/l, respectively). Glycosaminoglycans 39-42 interferon gamma Homo sapiens 21-30 8836130-3 1996 IFN gamma (250 i.u./ml) induced an increase in incorporation of D-[1-3H]glucosamine into glycosaminoglycans, either secreted into the culture medium or associated with the cell layer. Glycosaminoglycans 89-107 interferon gamma Homo sapiens 0-9 1511700-10 1992 This study shows that IFN-gamma regulates cell behavior in three-dimensional collagen matrices: (i) it decreases protein and specifically glycosaminoglycan synthesis in scleroderma fibroblasts, (ii) it modulates the interactions between cells and matrix that lead to the retraction of the lattice. Glycosaminoglycans 138-155 interferon gamma Homo sapiens 22-31 8674529-2 1996 Considering 3H incorporation, we found that IFNgamma increased the production of glycosaminoglycan synthesis, including hyaluronic acid, heparan and chondroitin/dermatan sulfate. Glycosaminoglycans 81-98 interferon gamma Homo sapiens 44-52 1525174-1 1992 Interferon-gamma binds to the glycosaminoglycan part of basement membrane proteoglycan. Glycosaminoglycans 30-47 interferon gamma Homo sapiens 0-16 2258640-9 1990 This is in accord with in vitro studies showing that, while interferons alpha and beta decrease production of glycosaminoglycans, IFN-gamma increases production of glycosaminoglycans. Glycosaminoglycans 164-182 interferon gamma Homo sapiens 130-139 1902486-0 1991 Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. Glycosaminoglycans 15-32 interferon gamma Homo sapiens 49-65 1902486-2 1991 We treated cultured retroocular and dermal fibroblasts with recombinant interferon gamma (100 U/ml) for 16-24h and measured [3H]GAG accumulation. Glycosaminoglycans 128-131 interferon gamma Homo sapiens 72-88 1902486-5 1991 These results suggest that retroocular fibroblasts may be uniquely targeted for one action of interferon gamma which involves the modulation of GAG metabolism. Glycosaminoglycans 144-147 interferon gamma Homo sapiens 94-110 1900310-7 1991 Furthermore, the carboxy-terminal part of the interferon-gamma molecule contains an amino acid cluster, very closely related to a consensus sequence, present in more than 20 proteins known to bind sulfated glycosaminoglycans such as heparin. Glycosaminoglycans 206-224 interferon gamma Homo sapiens 46-62 33859108-9 2021 P2 demonstrated a striking increase in the frequency of gag-specific central and effector memory CD8+ T cells producing IFN-gamma, TNF-alpha, and CD107a following anti-PD1 and anti-CTLA-4. Glycosaminoglycans 56-59 interferon gamma Homo sapiens 120-129 2117000-6 1990 IFN-gamma exerted an antagonistic effect on the TGF-beta-induced stimulation of GAG synthesis. Glycosaminoglycans 80-83 interferon gamma Homo sapiens 0-9 2500974-5 1989 Thus, IFN-gamma opposes the stimulatory effect of IL-1 on caseinase production and decreases IL-1-stimulated cartilage degradation, as measured by glycosaminoglycan release. Glycosaminoglycans 147-164 interferon gamma Homo sapiens 6-15 2448341-13 1988 These studies demonstrate that IFN-gamma, TNF, and LT are important stimulators of fibroblast GAG biosynthesis, that interactions between these cytokines may be important in this regulatory process, that these cytokines predominantly stimulate hyaluronic acid production and that this effect may be mediated by stimulation of fibroblast hyaluronate synthetase activity. Glycosaminoglycans 94-97 interferon gamma Homo sapiens 31-40 27427967-6 2016 Priming with BCG-GagM and boosting with MVA-GagM elicited higher Gag-specific IFN-gamma ELISPOT responses than the BCG-GagM only and MVA-GagM only homologous vaccination regimens. Glycosaminoglycans 17-20 interferon gamma Homo sapiens 78-87 30921340-8 2019 It was observed that DNA priming and MVA boosting induced Env and Gag specific bi-functional and multi-functional CD4+ and CD8+ T cells expressing IFN-gamma, TNF-alpha and IL-2. Glycosaminoglycans 66-69 interferon gamma Homo sapiens 147-156 28969431-5 2018 After three HIV-DNA immunizations, IFN-gamma ELISpot responses to Gag were detected in 9/17 (53%) vaccinees, while none responded to Envelope (Env). Glycosaminoglycans 66-69 interferon gamma Homo sapiens 35-44 28179527-8 2017 For granzyme B, Tat/Rev was the most dominant whereas for IFN-gamma, Gag predominated. Glycosaminoglycans 69-72 interferon gamma Homo sapiens 58-67 27502245-9 2016 NO production and GAG release by the cartilage was increased when cultured with M(IFNgamma+TNFalpha) MCM. Glycosaminoglycans 18-21 interferon gamma Homo sapiens 82-90 30564243-6 2018 In vitro study shows that IL-33 promotes the expression of IFN-gamma by Gag stimulated CD4+ and CD8+T cells from HIV-infected patients to a certain extent. Glycosaminoglycans 72-75 interferon gamma Homo sapiens 59-68 28333940-6 2017 At 20 WPV, the most significant transcriptional changes of Gag-specific CD8+ T cells were genes involved in TCR signaling, differentiation and maturation toward central memory cells, with increased expression of CCR7, TCRalpha, TCRbeta, CD28 and decreased expression of CTLA-4, IFN-gamma, RANTES, granzyme A and B. Glycosaminoglycans 59-62 interferon gamma Homo sapiens 278-287